The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases
Post Reproductive Health · 2025
DOI: 10.1177/20533691251369205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Post Reproductive Health, 2025. Verfasst von Phoebe Howells und 7 weiteren Autor:innen. Beteiligte Einrichtung: Princess Royal University Hospital, Orpington, UK. Hauptthemen laut MEDLINE: Estradiol, Venous Thromboembolism, Thromboembolism, Estrogen Replacement Therapy. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the risk of further thrombosis with using HRT containing transdermal estradiol in women with a personal history of venous thromboembolism (VTE) or arterial thromboembolism (ATE).
Methods
We undertook analysis of patients with a history of VTE/ATE who had been seen in the menopause clinic at King’s College Hospital. They were followed up for a minimum of a 12 months period to assess for recurrence of VTE/ATE.
Results
The study included 115 patients with a personal history of VTE/ATE who had used HRT for over a year. 81% had a history of a VTE, 19% had suffered from an ATE. Patients had taken HRT containing transdermal estradiol +/− micronised progesterone or Mirena coil or combined transdermal HRT for a range of 1–20 years, with an average duration of 3 years. 11 patients had switched from oral HRT to transdermal HRT after visiting the clinic. All patients had been referred to a haematologist with 20% of patients requiring life-long anticoagulation based on their medcial background history. 64% of the patients had documented thrombophilia results with 42% of those being positive for a thrombophilia. 39/115 patients required a higher dose of estrogen, taking either more than two pumps of gel/spray or >50 micrograms in the form of a patch. Significantly on follow up (up to 12 months or more), none of the patients had a recurrence of a thromboembolism within 12 months of starting HRT containing transdermal estradiol.
Conclusion
To our knowledge, this is the first study assessing the use of HRT containing transdermal estradiol in women with a personal history of VTE/ATE. None of the patients assessed had a thromboembolic event within 12 months of follow up. This study will enable more clinicians to consider prescribing HRT in patients with a personal history of VTE/ATE and higher patient uptake, after individualised risk-assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Royal University Hospital, Orpington, UK.
- King's College Hospital, London, UK.
- King's College Hospital Fertility, London, UK.
ORCID-Profile: Phoebe Howells, Haitham Hamoda
Zitieren
APA
Howells, P., Hussain, S., Hulme, E., Vigneswaran, K., Zia, S., Hassan, M., Arya, R., & Hamoda, H. (2025). The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases. Post Reproductive Health. https://doi.org/10.1177/20533691251369205
Vancouver
Howells P, Hussain S, Hulme E, Vigneswaran K, Zia S, Hassan M, et al. The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases. Post Reproductive Health. 2025. doi:10.1177/20533691251369205
BibTeX
@article{Howells2025,
author = {Howells, Phoebe and Hussain, Sadiya and Hulme, Emily and Vigneswaran, Kugajeevan and Zia, Samar and Hassan, Mohsen and Arya, Roopen and Hamoda, Haitham},
title = {The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases},
journal = {Post Reproductive Health},
year = {2025},
doi = {10.1177/20533691251369205}
}
EUVIMED